Literature DB >> 23577866

Hepatitis B and C infection in international travelers.

Douglas F Johnson1, Karin Leder, Joseph Torresi.   

Abstract

BACKGROUND: Hepatitis B and C virus (HBV and HCV) cause significant morbidity and mortality worldwide. With the rise in international travel over the last three decades, many travelers are at risk of HBV and HCV infection.
METHODS: This review focuses on the epidemiology of HBV and HCV in international travelers, the modes of transmission, and the prevention of infection in travelers.
RESULTS: The risk of HBV and HCV infection varies widely and depends on the prevalence of the destination country, the duration of travel, and the activities undertaken while abroad. Travelers commonly undertake high-risk activities that place them at risk of both HBV and HCV infection. Poor uptake of preventative health measures and poor adherence to health recommendations are also common. The monthly incidence of HBV infection for long-term travelers to endemic countries ranges from 25 to 420 per 100,000 travelers. HBV infection can be prevented through timely vaccination of travelers. HBV vaccination is safe and efficacious with protective levels of antibodies achieved in >90% of recipients. Information regarding the risk of HCV acquisition is scarce and until recently was limited to case reports following medical interventions.
CONCLUSIONS: This review demonstrates international travelers are at risk of HBV and HCV infection and provides evidence-based information enabling health practitioners to provide more appropriate pre-travel advice. HBV vaccination should be considered in all travelers to countries with a moderate to high HBV prevalence (HBsAg ≥ 2%) and the risk and benefits discussed with the individuals in consultation with the health practitioner. There is no duration of travel without risk of HBV infection. However, it is apparent that those travelers with a longer duration of travel are at greatest risk of HBV infection (ie, expatriates). Travelers should also receive advice regarding the modes of transmission and the activities that place them at risk of both HBV and HCV infection.
© 2013 International Society of Travel Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23577866     DOI: 10.1111/jtm.12026

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  6 in total

1.  Hepatitis B vaccination coverage among adults aged ≥ 18 years traveling to a country of high or intermediate endemicity, United States, 2015.

Authors:  Peng-Jun Lu; Alissa C O'Halloran; Walter W Williams; Noele P Nelson
Journal:  Vaccine       Date:  2018-03-28       Impact factor: 3.641

2.  Rapid detection of hepatitis B virus in blood plasma by a specific and sensitive loop-mediated isothermal amplification assay.

Authors:  Dougbeh-Chris Nyan; Laura E Ulitzky; Nicoleta Cehan; Phillip Williamson; Valerie Winkelman; Maria Rios; Deborah R Taylor
Journal:  Clin Infect Dis       Date:  2014-04-04       Impact factor: 9.079

3.  Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.

Authors:  Peng-Jun Lu; Mei-Chuan Hung; Anup Srivastav; Lisa A Grohskopf; Miwako Kobayashi; Aaron M Harris; Kathleen L Dooling; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Walter W Williams
Journal:  MMWR Surveill Summ       Date:  2021-05-14

4.  Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug-drug interactions and hepatitis C cure.

Authors:  Salamat Ali; Tofeeq Ur-Rehman; Eleri Lougher; David Mutimer; Mashhood Ali; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2020-02-25

Review 5.  Hepatitis B vaccination for international travelers to Asia.

Authors:  Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Patiwat Sa-Angchai; Chayasin Mansanguan; Watcharapong Piyaphanee
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-08-17

6.  Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Sarah Schillie; Claudia Vellozzi; Arthur Reingold; Aaron Harris; Penina Haber; John W Ward; Noele P Nelson
Journal:  MMWR Recomm Rep       Date:  2018-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.